Switch theme
Sign up to access all valuation multiples
Nahdi Medical Co is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods, and medical equipment. It has two operating segments Front Shop and Pharma.
1986
n/a
LTM Revenue $2.6B
LTM EBITDA $436M
$4.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nahdi Medical has a last 12-month revenue (LTM) of $2.6B and a last 12-month EBITDA of $436M.
In the most recent fiscal year, Nahdi Medical achieved revenue of $2.5B and an EBITDA of $430M.
Nahdi Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nahdi Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Profit | $977M | XXX | $943M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $436M | XXX | $430M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $241M | XXX | $231M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $222M | XXX | $219M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nahdi Medical's stock price is SAR 122 (or $33).
Nahdi Medical has current market cap of SAR 15.9B (or $4.2B), and EV of SAR 16.5B (or $4.4B).
See Nahdi Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.4B | $4.2B | XXX | XXX | XXX | XXX | $1.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nahdi Medical has market cap of $4.2B and EV of $4.4B.
Nahdi Medical's trades at 1.7x EV/Revenue multiple, and 10.2x EV/EBITDA.
Equity research analysts estimate Nahdi Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nahdi Medical has a P/E ratio of 19.1x.
See valuation multiples for Nahdi Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV (current) | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBIT | 18.3x | XXX | 19.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.1x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | 21.6x | XXX | 14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNahdi Medical's last 12 month revenue growth is 7%
Nahdi Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Nahdi Medical's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nahdi Medical's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nahdi Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nahdi Medical acquired XXX companies to date.
Last acquisition by Nahdi Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Nahdi Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nahdi Medical founded? | Nahdi Medical was founded in 1986. |
| Where is Nahdi Medical headquartered? | Nahdi Medical is headquartered in Saudi Arabia. |
| Who is the CEO of Nahdi Medical? | Nahdi Medical's CEO is Mr. Yasser Ghulam Abdulaziz Joharji. |
| Is Nahdi Medical publicy listed? | Yes, Nahdi Medical is a public company listed on SAU. |
| What is the stock symbol of Nahdi Medical? | Nahdi Medical trades under 4164 ticker. |
| When did Nahdi Medical go public? | Nahdi Medical went public in 2022. |
| Who are competitors of Nahdi Medical? | Similar companies to Nahdi Medical include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Nahdi Medical? | Nahdi Medical's current market cap is $4.2B |
| What is the current revenue of Nahdi Medical? | Nahdi Medical's last 12 months revenue is $2.6B. |
| What is the current revenue growth of Nahdi Medical? | Nahdi Medical revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Nahdi Medical? | Current revenue multiple of Nahdi Medical is 1.7x. |
| Is Nahdi Medical profitable? | Yes, Nahdi Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nahdi Medical? | Nahdi Medical's last 12 months EBITDA is $436M. |
| What is Nahdi Medical's EBITDA margin? | Nahdi Medical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Nahdi Medical? | Current EBITDA multiple of Nahdi Medical is 10.1x. |
| What is the current FCF of Nahdi Medical? | Nahdi Medical's last 12 months FCF is $203M. |
| What is Nahdi Medical's FCF margin? | Nahdi Medical's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Nahdi Medical? | Current FCF multiple of Nahdi Medical is 21.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
